Sernova and Seraxis Enter Definitive Merger Agreement to Create a Differentiated Type 1 Diabetes Islet Cell-Replacement Biotech Company, BetaNova Biotherapeutics

Investors

View Stock Information
Corporate presentation image
Corporate Presentation (PDF)

Corporate Profile

Sernova is a regenerative medicine company developing therapeutic technologies with multibillion-dollar market potential for each of its clinical indications.

Press Releases

September 10, 2026
Sernova Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investor Conference
September 8, 2026
Sernova and Seraxis Enter Definitive Merger Agreement to Create a Differentiated Type 1 Diabetes Islet Cell-Replacement Biotech Company, BetaNova Biotherapeutics
June 17, 2026
Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy
View All Press Releases

Events

September 11, 2026 ET
Sernova Biotherapeutics, Inc. Shareholder Webinar
April 8, 2026 ET
Annual General and Special Meeting of Shareholders
December 13, 2024 ET
Sernova Virtual Investor Event: Meet Our Leadership
View All Events

IR Contact


David Burke
Vice President, Investor Relations
917.751.5713
david.burke@sernova.com

Email Alerts Sign-Up

Scroll to Top